
This review synthesizes recent evidence on the role of sleep in memory consolidation and updating, focusing on the underlying neural mechanisms and their control. Recent literature demonstrates that memory encoding is followed by a labile window during which memory traces are subject not only to consolidation but also to updating. Sleep after single-shot learning can stabilize or enhance memory, rendering it resistant to subsequent natural forgetting. In addition, sleep following multiple experiences supports further forms of memory processing, including reconsolidation, extinction, integration, and differentiation. These processes are mediated by neural circuitry dynamics coupled with electrophysiological oscillations and neuromodulatory rhythms across sleep states. Furthermore, memory processing during sleep can be experimentally controlled by manipulating these internal fluctuations or through targeted memory reactivation. Sleep-dependent processing of existing and newly acquired memories is governed by dissociable state-specific mechanisms, which are increasingly amenable to experimental control.
Sudden unexpected death in epilepsy (SUDEP) remains the leading cause of epilepsy-related mortality. While heterogeneous in its pathophysiology, a significant proportion of cases are likely attributable to cardiorespiratory collapse following a convulsive seizure. We synthesize recent mechanistic, biomarker, and prevention literature, moving from retrospective risk inference toward individualized action. Human and animal data support a multiple hit model, in which seizure-induced cardiorespiratory dysfunction is necessary but not necessarily sufficient for death: the environment, genetic susceptibility, sleep and circadian state, and potentially as yet unidentified factors determine which seizures prove fatal. The Mortality in Epilepsy Monitoring Units study (MORTEMUS) provided key insights into SUDEP pathophysiology, while multicenter prospective studies continue to examine SUDEP risk factors and mechanisms, and elucidate candidate biomarkers for individual risk stratification. Prevention is slowly moving beyond mainstays of nocturnal supervision and antiseizure therapies, guided by data from animal models of seizure-associated death. Emerging technologies such as seizure detection devices are being widely deployed to enhance protection, though none has been shown in a randomized trial to reduce SUDEP. Efforts toward universal SUDEP education and counseling not only address legal and moral disclosure responsibilities, but encourage patient autonomy and informed decision-making for individual risk reduction. The decade following publication of the MORTEMUS study continues to provide new insights into SUDEP pathophysiology, propose novel candidate biomarkers and offer potential intervention targets. While obstacles remain in the replication of putative clinical biomarkers and the translation of promising findings from animal models, enhancing SUDEP knowledge and effective patient counseling are critical to improving outcomes and saving lives.
Patients with brain tumors have a plethora of potential complications that arise from both the tumor and its therapeutic management. These complicate clinical management and produce morbidity and occasionally mortality. In this review we discuss the most common neurological and medical complications that include tumor-related epilepsy, vasogenic edema, infection, thromboembolism, endocrine abnormalities and cognitive impairment and its management. This review is an update to the 2020 article by Schiff and Alyahya. IDH mutant gliomas cause neuronal hyperexcitability via D-2 -hydroxyglutarate production; use of IDH inhibitors may lower the rate of seizures in this patient population. Pneumocystis prophylaxis with antibiotics has been traditionally recommended with radiation and concurrent temozolomide chemotherapy but newer data suggest no difference in hospitalization or survival. Podoplanin produced by tumor cell releases into the circulation, often via extracellular vesicles, activates platelets and may contribute to venous thrombus formation. Direct oral Anticoagulants (DOACs) are the treatment of choice for venous thromboembolism, with high quality of evidence and a strong recommendation in cancer-associated thrombosis. Though brain tumor patients were underrepresented in clinical trials, retrospective studies support its safety in this population. Brain tumor patients are prone to complications arising from both the tumor and the treatment strategies. Management requires a multidisciplinary strategy with supportive medications including antiseizure medications, corticosteroids, anticoagulants for thromboembolism, and neurocognitive rehabilitation. Early recognition and timely intervention can reduce the morbidity associated with these complications leading to better patient outcomes.
GAD65 autoimmune-associated epilepsy (AAE) is an underrecognized cause of epilepsy with common delays to immunotherapy. We review advances in its pathophysiology, diagnosis and management. GAD65 AAE predominantly affects young women, presenting as drug resistant temporal lobe epilepsy (TLE), often without mesial temporal sclerosis. Patients lie within a continuum where T cell mediated inflammation predominates in early disease, temporally overlapping with progressive structural injury, which leads to chronic epilepsy. Diagnosis is supported by high-level antibody detection in serum (RIA > 20 nmol/L or > 2000 U/mL, ELISA > 10,000 IU/mL), and in select cases CSF testing may be helpful. Treatment requires both immunotherapy and antiseizure medications. Immunotherapy response is greatest in early disease but can occur at later stages. Epilepsy surgery workup and neuromodulation may benefit some patients, although seizure freedom is rare. GAD65 AAE can resemble non-autoimmune TLE. Phenotype-based antibody testing and early recognition are important to guide timely, individualized treatment.
Timely and accurate diagnosis of central nervous system (CNS) infections remains challenging because of nonspecific clinical characteristics and limited diagnostic accuracy of conventional tests. Novel cerebrospinal fluid (CSF) biomarkers may improve early diagnosis and facilitate differentiation between infectious aetiologies. This review summarizes established and emerging CSF biomarkers for the diagnosis of CNS infections, with a focus on bacterial meningitis, and discusses their potential clinical application. Several novel CSF biomarkers have demonstrated excellent diagnostic performance for bacterial meningitis. Among these, CSF C-reactive protein (CRP) has recently been implemented in clinical practice, while heparin-binding protein and combinations of CSF CRP with inflammatory cytokines such as IL-6 and IL-1β show similarly high diagnostic accuracy. Pathogen-specific biomarkers, including CXCL13 for neuroborreliosis and β-D-glucan and galactomannan for fungal CNS infections, further expand the diagnostic repertoire. In addition, multi-omics approaches, including metabolomics, lipidomics, and proteomics, have identified promising candidates such as pyruvate and phosphatidylcholines, although these require further validation. Untargeted techniques, including metagenomic next-generation sequencing and phage immunoprecipitation sequencing, further enhance pathogen detection and may complement microbiological testing. Novel biomarkers have the potential to substantially improve the diagnosis of CNS infections. Several biomarkers for bacterial meningitis are already available for clinical implementation, particularly in patients with intermediate CSF leukocyte counts, where diagnostic uncertainty is greatest. For viral and other CNS infections biomarkers remain scarce. Future studies should focus on validation of emerging biomarkers and on integrating biomarker panels with advanced molecular diagnostic techniques to enable rapid, accurate and clinically applicable diagnostic strategies.